Courtesy Marilyn Mann, from a CNN article, of yesterday afternoon:
. . . .Niaspan prescriptions among new patients who hadn't taken any cholesterol drug in the previous 12 months rose 33.8% from the previous week, while prescriptions on that basis for Zetia dropped 24% and were down 16.8% for Vytorin. New Niaspan prescriptions among people who had taken a different cholesterol drug in the previous 12 months rose 45.6% from the week before, while Zetia declined 27.4% and Vytorin dropped 23.7% on similar bases.
Merck spokesman Ron Rogers said the company isn't familiar with the SDI data, and that it would be "premature" to gauge the impact of the Arbiter 6 study on market trends. . . .